Allogeneic natural killer cells for refractory lymphoma - Test2 - elhamkhani - TriplyDB

Allogeneic natural killer cells for refractory lymphoma

Allogeneic natural killer cells for refractory lymphoma

http://www.wikidata.org/entity/Q33850138

about

Natural Killer Cells for Therapy of Leukemia Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies Understanding of molecular mechanisms in natural killer cell therapy Improving natural killer cell cancer immunotherapy NK cells in therapy of cancer Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro.Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.Attribution of NKG2DL to the inhibition of early stage allogeneic tumors in mice.Role of Natural Killer Cells in HIV-Associated Malignancies.Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.Targeting natural killer cells and natural killer T cells in cancer.The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses.Clinical utility of natural killer cells in cancer therapy and transplantation.Clinical grade purification and expansion of natural killer cells.Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.Natural Killer Cell Immunotherapy: From Bench to Bedside

P2860

Q26745906-9D9E4B7F-0AE6-493C-B9BF-8E8AB8BAD7FA Q26765115-14B9B54A-16C4-479B-ADEE-4A13EF081E3B Q27309991-FFB2C6BE-F8B4-494E-AD90-04BF615C9113 Q28079180-15B1EA9B-B082-4667-9BE5-15207AEB9715 Q28086976-112D3259-F011-4F25-90FF-6F8474871CB9 Q28087719-5616E055-3FB6-48C9-AB22-A3211D622324 Q28242241-CF56011B-9324-476C-BBCE-2970C9DA430A Q33715830-FA3107AD-8A6B-4387-8D62-C594994865EF Q33781150-489D91CB-73BF-4ED6-B659-AC175B8AEB57 Q33785788-2825F5AC-F137-4D85-91C5-3F92914BD2F0 Q33905311-BE1D3F27-AFA7-4308-BD26-A902CEB06001 Q33922539-02999C61-2602-4535-8CA3-DA664BC6A9E7 Q34307792-FA276032-7271-49E7-8964-8C17F798B828 Q34571639-76B0FDDE-A5A4-4527-8EF4-089A01B20ADD Q34618454-D27AA348-E411-4663-81BD-50019770DA93 Q35177618-A880E08E-0562-4559-9085-973A9906CC56 Q35600095-3C2039B6-3C59-4367-8838-67C56951E228 Q35752181-F23667BC-68F2-4F8D-BC2C-FEA912ED8015 Q35963440-779B0BE9-8447-4F73-89DE-F6F86E1B7AF0 Q36187369-A7FC1B0D-1EF3-41D8-BFEE-C152708A43AA Q36478280-52450867-700C-442A-AD1C-603FB73F575D Q36712059-685C5807-A38C-4CFF-B070-C8D8F394C804 Q36856792-71C8DF6F-46F2-4DC2-950F-018E88C225D1 Q36999109-1B19C6CA-4D9D-4926-8341-70990E0FFFF7 Q37261189-CCD1ECBD-3965-4682-911D-B21CF43F8327 Q37565475-FBB7C0F2-B370-404B-864C-4BD4AEC23CF1 Q37579561-6B05F80E-95AD-4189-BD9C-3D52A3785765 Q37589671-C0AAD14A-8465-4B29-85AF-DC6DB77D3233 Q37637949-B4121605-7F1B-4B77-9183-DC79A52B3AEF Q37696132-DD7686A3-4C50-46C4-BEF2-7FA4D340297B Q37712593-173862BC-53C8-4E1C-8AAE-84DFA155AA74 Q37905034-624CA479-149F-4A05-9F48-53EFE79ACAF8 Q37993738-26C2FC49-ACAB-40B8-B05D-1C23256ACF46 Q37995950-6C99A2B1-2CA0-4D14-8A8B-400E1B436BA1 Q38073762-4AA97570-3590-4FC3-B4EA-83AC3CAE8CA9 Q38195120-F86818DC-48A4-4F7A-A3A2-3A93912B3958 Q38221228-88093F01-766B-4C82-BF0F-1C6D21CD2520 Q38233046-2AC2146D-AA0C-4D78-9C68-C6890A5D81BB Q38513534-F1C5E054-A97E-4A52-8E7A-250A3448C1B0 Q38531958-36DCFA3D-1C7A-4CEE-AEB1-C3F1C7F5C51F

P2860

Allogeneic natural killer cells for refractory lymphoma

http://www.wikidata.org/entity/Q33850138

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Allogeneic natural killer cells for refractory lymphoma

@ast

Allogeneic natural killer cells for refractory lymphoma

@en

type

label

Allogeneic natural killer cells for refractory lymphoma

@ast

Allogeneic natural killer cells for refractory lymphoma

@en

prefLabel

Allogeneic natural killer cells for refractory lymphoma

@ast

Allogeneic natural killer cells for refractory lymphoma

@en

P1433

Q33850138-AF2B9F52-86F0-4BE4-A420-C27DA5BC4867

P1476

Q33850138-3D447B2A-97AB-4828-B829-B9705FA6ECF8

P2093

Q33850138-576CFD87-B9B0-45EE-BA79-7A2C6021969C

Q33850138-5B3F2FAD-E886-4FDE-97A5-B2682F72961C

Q33850138-6935FB2E-2A01-4092-A5DE-D5B9D9816CFB

Q33850138-6AE12BCF-B5AF-4154-80B0-4CA087A181DE

Q33850138-9248AF20-FD45-46F7-807A-90D402C8DD47

Q33850138-A725489D-93E2-433E-A795-3F6CD2B3CAB1

Q33850138-E3E4E465-9BDE-4F12-8651-3E4D1C69CF63

Q33850138-F9595732-AAAE-43E0-9F10-F929723F6AB4

P2860

Q33850138-1932D355-BAF1-4908-B4CE-D3E998B5810C

Q33850138-3781A218-AD06-4A80-A824-969655008FDB

Q33850138-417E94FF-7B25-417D-BE19-41DD08EF0C7A

Q33850138-429DE982-3077-4C02-94CB-B377F83708F8

Q33850138-5031B473-2314-4F9B-A14C-589C72D728BF

Q33850138-520511F1-2312-4A49-BCD6-063C68522C7D

Q33850138-55D922BA-D7E5-4C76-ACF0-AA80D98AE987

Q33850138-601E6646-1D54-4BD6-AF0C-D2728881A867

Q33850138-6A7F58A3-85FF-4BC5-AAD3-8EC20BE969B4

Q33850138-6D641788-0EB5-41A7-84AF-4F409FD2EADD

P2888

Q33850138-FF176D21-BD33-4C15-B5B3-DA42548F4F34

P304

Q33850138-8B2B7715-548C-4D8E-B43F-74A794288F55

P31

Q33850138-CD2A1377-DE61-4546-A107-802C6E452B81

P356

Q33850138-E14D9339-4AAC-48F2-AF21-C357113B7D7A

P433

Q33850138-92C58BB2-EA19-4DD4-8FC2-4C4369607004

P478

Q33850138-961F7727-9B18-403A-B092-F0773A3F71FC

P50

Q33850138-1DFD7B9B-F567-4C1A-A6AA-735D7B9E5F45

P577

Q33850138-C9F9B491-AB44-4AD9-9D9C-6B31C33140A7

P6179

Q33850138-19628DAD-D4E8-4FA2-9C92-CEF0588B8E07

P698

Q33850138-D0685BDB-F945-48A8-B79B-684F4C554D76

P932

Q33850138-7688A97F-EE62-46E3-B3D4-4E96D1167668

P356

S00262-010-0896-Z

P1433

Cancer Immunology, Immunotherapy

P1476

Allogeneic natural killer cells for refractory lymphoma

@en

P2093

Bruce R Lindgren

http://www.w3.org/2001/XMLSchema#string

Daniel Weisdorf

http://www.w3.org/2001/XMLSchema#string

David H McKenna

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Miller

http://www.w3.org/2001/XMLSchema#string

Julie Curtsinger

http://www.w3.org/2001/XMLSchema#string

Linda J Burns

http://www.w3.org/2001/XMLSchema#string

Sarah Cooley

http://www.w3.org/2001/XMLSchema#string

Veronika Bachanova

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells

Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells.

NK cells and Treg cells: a fascinating dance cheek to cheek.

Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.

P2888

s00262-010-0896-z

P304

1739-1744

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0896-Z

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Angela Panoskaltsis-Mortari

P577

2010-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1015126438

http://www.w3.org/2001/XMLSchema#string

P698

20680271

http://www.w3.org/2001/XMLSchema#string

P932

4082975

http://www.w3.org/2001/XMLSchema#string